Company news
Curasight A/S news in 2026
Curasight A/S's news releases, calls and decks from 2026, newest first.
Curasight Announces protocol update for the Phase I uTREAT trial in Aggressive Brain Cancer (Glioblastoma)
July 27, 2026
Curasight A/S has successfully completed a directed issue of shares of approximately DKK 20 million
June 22, 2026
Curasight A/S announces its intention to carry out a directed issue of shares
June 22, 2026
Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT[®] in Aggressive Brain Cancer (Glioblastoma)
June 8, 2026
Curasight: Major Shareholding Notification - share transfer and ownership restructuring – related party transaction
April 26, 2026
Major Shareholding Notification - share transfer and ownership restructuring - related party transaction
April 26, 2026
Resolutions of the Annual General Meeting 2026 of Curasight A/S
March 25, 2026
Curasight: Notice of Annual General Meeting 2026
March 10, 2026
Curasight reduces debt through Fenja Capital conversion
March 9, 2026
Curasight reduces convertible debt as Fenja Capital converts and enters into a block trade
March 6, 2026
Curasight: Major Shareholding Notification
February 9, 2026
Major Shareholding Notification
February 9, 2026
Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®
January 12, 2026
Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
January 5, 2026